COVID-19 Vaccine Side Effect Tracker

covid-19 vaccine side effect tracker

Most Recent Updates:

Click the dates to jump to more details.

  • September 28: The CDC released data showing that the side effects of a third shot of Pfizer’s vaccine are similar to those of the second shot.
  • September 2: Researchers in Israel reviewed medical records of patients who had experienced Guillan-Barre Syndrome (GBS) prior to receiving Pfizer’s COVID-19 shot. Of the 579 patients, five were transferred to the hospital for neurological symptoms such as tremors or prickling sensations. Only one patient required medical care for relapse of GBS.
  • August 22: Researchers published two case studies of patients experiencing neurological effects such as losing balance and non-epileptic convulsions after the Pfizer and AstraZeneca vaccines. They emphasize that functional neurological disorders are treatable.
  • August 19: The FDA and CDC are investigating the possibility that Moderna’s vaccine could be up to 2.5 times more likely to be associated with myocarditis (heart inflammation), especially for males under 30 years old. If true, the effect would still be exceedingly rare and scientists say the benefits still greatly outweigh the harms of vaccination. Most patients recover on their own with minimal intervention.
  • August 18: The FDA and CDC authorized third shots for patients with specific conditions that compromise their immune systems. The Biden administration has also pushed for booster shots to be made available to everyone, eight months after their second dose, in response to waning antibody levels and a rise in breakthrough infections. People who took Pfizer, Moderna or J&J’s vaccines are still highly protected against hospitalization and death. This plan is not yet authorized. The agencies are also waiting for data to provide guidelines specific to J&J vaccine recipients in the coming weeks.
  • July 12: The FDA is attaching a warning to the Johnson & Johnson vaccine about a slightly elevated risk of developing Guillain-Barre syndrome within three weeks of receiving the vaccine. The benefits still out weight the risks of vaccination, it says.
  • June 23: About 1.9% of healthcare employees who received an mRNA vaccination had a skin reaction such as itching or a rash after the first dose. Most (83%) who reported a skin reaction after the first dose, did not experience it again after the second dose, according to a study today in JAMA Dermatology. Another 2.3% experienced a skin reaction after only the second dose.

To help you sort through the news on the COVID-19 vaccine’s progress, MedShadow has created the MedShadow Vaccine Tracker, the only tracker focused on the side effects and adverse events associated with proposed COVID-19 vaccinations.

Rather than injecting patients with a weakened virus or proteins from the pathogen that our immune systems can recognize, which is what’s typically done when we get a flu vaccine, the new vaccines from Moderna and Pfizer — the two that made it to the market first in the U.S. — contain mRNA (messenger RNA), which is a genetic template that instructs our cells to build the viral proteins that our immune systems can then recognize. Its main perk is that allowing our bodies to produce the proteins (rather than growing them in a lab like traditional vaccines) slashes production time. For nearly 20 years, researchers have been interested in using mRNA in vaccines; and some were even tested in early clinical trials for rabies, influenza and Zika. However, the vaccines for COVID-19 will be the first mRNA vaccines ever authorized by the FDA.

Some risks and minor side effects, such as a sore arm where the vaccine is injected or a light skin rash, are clearly worth the benefit of being protected against a disease. Where to draw the line at what is or is not acceptable is a personal decision. That’s where the MedShadow Vaccine Tracker can help. 

On the tracker, we will be publishing up-to-date Phase 3 results information about the risks of each vaccination. Phase 3 tests the vaccine for safety and efficacy in large groups of people (tens of thousands) and is the last stage before the FDA considers approval for use in the population at large. We continue following verified reports as the vaccines are offered to the general public. It is important to note that reports of events occurring after vaccination are not inherently linked to it. As countries begin to vaccinate hundreds of millions of people, some would inevitably be diagnosed with illnesses or pass away each day with or without the injections.

Jump to:

ModernaPfizerCanSinBio (China) | Gameleya (Russia) | Johnson & Johnson

AstrazenecaNovavax (UK)Sinopharm (China)Sinovac (China)Murdoch (England)|Bharat Biotech

 


Moderna

Moderna started Phase III clinical trials for its vaccine candidate in July. In earlier trials, nearly half of patients experienced common adverse effects like injection site pain, rash, headaches, muscle soreness, nausea and fevers after the second injection. These effects generally subsided within two days. CNBC spoke to a few individuals, some participating in Moderna’s trial and some in Pfizer’s trial who said much the same thing: the side effects were intense and included a high fever, body aches, bad headaches and exhaustion, but were worth it for protection from Covid-19.

In the FDA report published in December, the most common side effects were pain at injection site (91.6% of patients), fatigue (68.5%), headache (63.0%), muscle pain (59.6%), joint pain (44.8%), and chills (43.4%). Three patients experienced Bell’s Palsy, a sudden, and usually temporary, weakening or paralysis of the facial muscles.

The CDC reports that 11% of patients experienced swollen lymph nodes after the first shot. That raised to 16% after the second shot.

A few patients with facial fillers experienced swelling after receiving the vaccine. They were treated with antihistamines and steroids.

January 18: In California, officials halted the use of one particular batch of Moderna vaccines (lot 41L20A) after a small cluster (fewer than 10) of patients at one particular site experienced allergic reactions that required medical attention.

February 1: A study posted on Feb 1 showed that patients who received the vaccine after having been previously infected with COVID-19 showed greater immune response to the first shot and more intense side effects that are associated with strong immune responses like fever and muscle aches. The study included patients who received either the Moderna or Pfizer vaccine. Some scientists believe these patients may only need a single shot to provide sufficient immunity, but more research is needed.

February 12: Out of the first 7.5 million doses administered from Dec 14- Jan 18, 19 cases of anaphylaxis were reported to VAERS after the Moderna vaccine. No patients have died from anaphylaxis. Patients are now being monitored for 15-30 minutes after receiving the vaccine to watch for signs of anaphylaxis. The CDC suggests that anyone who has an immediate allergic reaction to a single dose of an mRNA vaccine (Moderna or Pfizer) should not get the second dose. If your reaction was not immediate, you may be referred to an allergy specialist. The vaccines do not contain polysorbate, but do have a related ingredient, polyethylene glycol (PEG). If you have an allergy to either of these chemicals, you should not get the vaccines. 

Many patients are reporting injection site reactions that show up shortly after the injection or up to a week later. These reactions — which are characterized by swelling, redness, itching, rashes, heat and pain — are expected to last a day to a week. Physicians emphasize that while these effects can be scary, they are not dangerous and should not prevent someone from getting the second shot. So far, doctors do not report seeing these reactions after the second shot, however so few have been given so far that scientists are not sure how common it will be on round two.

March 3: Allergy researchers at Mass General Hospital created a registry for healthcare professionals to report  immediate and delayed reactions to COVID-19 vaccinations. On March 3, the researchers published a letter in the New England Journal of Medicine describing a series of 12 delayed injection site reactions including swelling and rashes. The researchers wrote that one patient received antibiotics although they were not necessary. Several others were treated with steroids or anti inflammatories. The letter included some photos and said that the reactions cleared up within a median of six days. Patients were encouraged to receive their second dose. Half of them did not experience the reaction the second time. A quarter did, but to a lesser degree.

March 8: Researchers from Mass General Brigham published a Research Letter in JAMA analyzing allergic reactions in employees who received their shots there. Out of 52,805 participants, 2.1% experienced some kind of allergic reaction, including hives, itching, rash, swelling or respiratory symptoms within the first three days after vaccination. Allergies were slightly more common with the Moderna vaccine than the Pfizer vaccine (2.2% compared to 1.95%). Sixteen experienced anaphylaxis.

Moderna has announced that it will begin testing its vaccine in children and adolescents, who they believe may have stronger immune responses, leading to more intense side effects.

April 20: Researchers have received over 25,000 responses to an online survey regarding menstrual changes after receiving any COVID-19 vaccine. The survey is ongoing as researchers hope to gain a better understanding of future directions of research. An op-ed in the New York Times explains how the vaccines could potentially interact with menstrual cycles, and why we really don’t know yet.

April 22: The CDC published an analysis of data from the first few months of voluntary V-safe surveys that suggested that the Moderna and Pfizer vaccines are safe for pregnant women. Pregnant patients self-reported slightly fewer side effects like fever, headache and chills than the general population, but more said they experienced nausea and injection site pain. Rates of adverse pregnancy outcomes such as pre-term birth were similar to rates seen before the pandemic. While promising, officials noted that more studies will be required.

April 26: MedShadow asked doctors about some of the unusual symptoms we’re hearing about in the comments: heart palpitations and visual disturbances. They hadn’t had patients who reported long-term symptoms, but said that if the symptoms occurred very quickly after vaccination, they could be related to allergic reactions or presyncope.

April 27: Clinical trials of Moderna and Pfizer vaccines showed 7 cases of Bell’s Palsy. An analysis published today in JAMA suggested the experience was no more frequent after these vaccines than other vaccines. It is unclear whether vaccines raise the risk of facial paralysis at all, but the authors write, “if an association between facial paralysis and mRNA COVID-19 vaccines exists, the risk is likely very low, as with other viral vaccines.”

May 5: Researchers published a detailed analysis of skin reactions after Moderna and Pfizer vaccinations, including swelling and rashes. Most patients with first dose reactions did not have reactions after their second dose. Larger reactions on the arm spreading outward from the injection site were the most common reactions among those who received the Moderna vaccine, followed by smaller localized reactions and hives. Five patients (1.9%) experienced a zoster (shingles) flare after the first dose but none after the second dose. About 1% of patients experienced a flare of an existing skin condition after each dose.

May 20: An analysis published in JAMA suggests that hearing loss is NOT a side effect of the Pfizer or Moderna vaccines.

June 10: The CDC says that as of May 31, VAERS had received 475 reports of myocarditis or pericarditis among people 30 years of age and younger who received a COVID-19 vaccine. Upon follow-up, the CDC and FDA confirmed 226 of the reports. They emphasize that more than 18 million people between ages 12-24 have received at least one dose of COVID-19 vaccine in the United States. A CDC Fact Sheet on the effect is available here.

June 23: About 1.9% of healthcare employees who received an mRNA vaccination had a skin reaction such as itching or a rash after the first dose. Most (83%) who reported a skin reaction after the first dose, did not experience it again after the second dose, according to a study today in JAMA Dermatology. Another 2.3% experienced a skin reaction after only the second dose.

August 18: The FDA and CDC authorized third shots for patients with specific conditions that compromise their immune systems. The Biden administration has also pushed for booster shots to be made available to everyone, eight months after their second dose, in response to waning antibody levels and a rise in breakthrough infections. People who took Pfizer, Moderna or J&J’s vaccines are still highly protected against hospitalization and death. This plan is not yet authorized. The agencies are also waiting for data to provide guidelines specific to J&J vaccine recipients in the coming weeks. Around a million people have gotten third shots so far in the US and abroad. The FDA hasn’t reviewed all of the data yet, but no new safety concerns have emerged thus far. See answers to frequently asked questions regarding the booster shots here.

August 19: The FDA and CDC are investigating the possibility that Moderna’s vaccine could be up to 2.5 times more likely to be associated with myocarditis (heart inflammation), especially for males under 30 years old. If true, the effect would still be exceedingly rare and scientists say the benefits still greatly outweigh the harms of vaccination. Most patients recover on their own with minimal intervention.


Pfizer

Pfizer began Phase III clinical trial for its vaccine candidate in July. In earlier trials, some patients experienced common adverse effects like injection site pain, rash, headaches, muscle soreness, nausea and fevers. These effects generally subsided within two days. CNBC spoke to a few individuals, some participating in Pfizer’s trial and others in Moderna’s trial who said much the same thing: the side effects were intense and included a high fever body aches, bad headaches and exhaustion in addition to the more common side effects, but were worth it for protection from Covid-19.

Some patients described the side effects as being similar to a bad hangover. A nurse who participated in the clinical trial reported feeling minimal effects after the first dose, but a fever that reached more than 104 degrees Fahrenheit after the second injection, along with chills, headache, and intense injection site pain. According to researchers, her experience of having all symptoms together was rare, though many patients had one or two of these side effects. “Clinicians will need to be prepared to discuss with patients why they should trust the vaccine and that its adverse effects could look a lot like COVID-19,” the nurse wrote on Dec 7.

The FDA report published in December said the most common reactions were injection site reactions (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint pain (23.6%), fever (14.2%). Swollen lymph nodes occurred in 0.3% of patients. The FDA reported that four patients who received the vaccine experienced Bell’s Palsy.

January 12: A doctor in Florida died 16 days after receiving the vaccine from a rare blood disorder, acute immune thrombocytopenia. Both Pfizer and the CDC are investigating, though the company has released a statement that so far, they haven’t seen any signs in the clinical trials or data collected from early vaccinations that the death could be related to the vaccine. The blood disorder immune thrombocytopenia, has also been seen as a rare complication of COVID-19 itself, in both symptomatic and asymptomatic patients.

January 19: Twenty-three elderly patients in Norway died after receiving Pfizer’s vaccine. Officials are investigating whether or not the deaths are vaccine-related. Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, suggests that while the deaths may be coincidental given the fragile population, it’s possible that side effects of the vaccines, like fevers, may have strained the frail patients’ bodies and contributed to their deaths. Norway has vaccinated about 45,000 people so far, most of whom live in nursing homes.

February 1: A study posted on Feb 1 showed that patients who received the vaccine after having been previously infected with COVID-19 showed greater immune response to the first shot and more intense side effects that are associated with strong immune responses like fever and muscle aches. The study included patients who received either the Moderna or Pfizer vaccine. Some scientists believe these patients may only need a single shot to provide sufficient immunity, but more research is needed.

February 12: Out of the first 9.9 million doses administered from Dec 14- Jan 18, 47 cases of anaphylaxis were reported to VAERS after the Pfizer vaccine. Patients are now being monitored for 15-30 minutes after receiving the vaccine to watch for signs of anaphylaxis. The CDC suggests that anyone who has an immediate allergic reaction to a single dose of an mRNA vaccine (Moderna or Pfizer) should not get the second dose. If your reaction was not immediate, you may be referred to an allergy specialist. The vaccines do not contain polysorbate, but do have a related ingredient, polyethylene glycol (PEG). If you have an allergy to either of these chemicals, you should not get the vaccines. 

March 8: Researchers from Mass General Brigham published a Research Letter in JAMA analyzing allergic reactions in employees who received their shots there. Out of 52,805 participants, 2.1% experienced some kind of allergic reaction, including hives, itching, rash, swelling or respiratory symptoms within the first three days after vaccination. Allergies were slightly more common with the Moderna vaccine than the Pfizer vaccine (2.2% compared to 1.95%). Sixteen experienced anaphylaxis.

March 30: Researchers publish a case study of a single patient in which they suspect the Pfizer vaccine may have caused a rheumatoid arthritis flare. The flare was treated, and the patient is in remission. The researchers and RA advocacy groups still advise patients to get the vaccine as the benefits outweigh the risks of a flare up.

April 20: Researchers have received over 25,000 responses to an online survey regarding menstrual changes after receiving any COVID-19 vaccine. The survey is ongoing as researchers hope to gain a better understanding of future directions of research. An op-ed in the New York Times explains how the vaccines could potentially interact with menstrual cycles, and why we really don’t know yet.

April 22: The CDC published an analysis of data from the first few months of voluntary V-safe surveys that suggested that the Moderna and Pfizer vaccines are safe for pregnant women. Pregnant patients self-reported slightly fewer side effects like fever, headache and chills than the general population, but more said they experienced nausea and injection site pain. Rates of adverse pregnancy outcomes such as pre-term birth were similar to rates seen before the pandemic. While promising, officials noted that more studies will be required.

April 26: MedShadow asked doctors about some of the unusual symptoms we’re hearing about in the comments: heart palpitations and visual disturbances. They hadn’t had patients who reported long-term symptoms, but said that if the symptoms occurred very quickly after vaccination, they could be related to allergic reactions or presyncope.

April 27: Clinical trials of Moderna and Pfizer vaccines showed 7 cases of Bell’s Palsy. An analysis published today in JAMA suggested the experience was no more frequent after these vaccines than other vaccines. It is unclear whether vaccines raise the risk of facial paralysis at all, but the authors write, “if an association between facial paralysis and mRNA COVID-19 vaccines exists, the risk is likely very low, as with other viral vaccines.”

May 5: Researchers published a detailed analysis of skin reactions after Moderna and Pfizer vaccinations, including swelling and rashes. Nearly a quarter of patients had smaller local reactions after each of the two shots. Hives were the most common skin reaction (26% after the first shot, 18% after the second,) among patients who received the Pfizer vaccine. Several also experienced flares of existing skin conditions.

May 10: Pfizer’s vaccine received Emergency Use Authorization for 12 to 15-year-olds. The company reported that common adverse effects like chills and fever were more common in this age group than adults. Adverse reactions in adolescents 12 through 15 years of age included pain at the injection site (90.5%), fatigue (77.5%), headache (75.5%), chills (49.2%), muscle pain (42.2%), fever (24.3%), joint pain (20.2%), injection site swelling (9.2%), injection site redness (8.6%), lymphadenopathy (0.8%), and nausea (0.4%). These effects generally subsided within 1-2 days. While data on syncope (fainting) was not included, the announcement mentioned that fainting after vaccination is more common in teens than adults, and that safety measures should be in place to reduce this risk.

May 20: An analysis published in JAMA suggests that hearing loss is NOT a side effect of the Pfizer or Moderna vaccines.

May 23: The CDC is investigating reports of myocarditis in a small number of vaccinated teens. Myocarditis, or inflammation of the heart, has multiple causes but a viral infection is the most common trigger. In 2019, one million people were diagnosed with myocarditis, most of them under 40 years old. It’s not yet clear if these events were related to the vaccine.

June 9: A study in Nature Medicine suggests that there may be a very slightly elevated risk of blood disorders after receipt of the AstraZeneca vaccine, but NOT Pfizer’s. The study was based on an analysis of medical records in Scotland. Researchers say the vaccine’s benefits still outweigh the risks and that their results should not alter policy. The rates are similar to those seen with other common vaccines.

June 10: The CDC says that as of May 31, VAERS had received 475 reports of myocarditis or pericarditis among people 30 years of age and younger who received a COVID-19 vaccine. Upon follow-up, the CDC and FDA confirmed 226 of the reports. They emphasize that more than 18 million people between ages 12-24 have received at least one dose of COVID-19 vaccine in the United States. A CDC Fact Sheet on the effect is available here.

June 23: About 1.9% of healthcare employees who received an mRNA vaccination had a skin reaction such as itching or a rash after the first dose. Most (83%) who reported a skin reaction after the first dose, did not experience it again after the second dose, according to a study today in JAMA Dermatology. Another 2.3% experienced a skin reaction after only the second dose.

August 18: The FDA and CDC authorized third shots for patients with specific conditions that compromise their immune systems. The Biden administration has also pushed for booster shots to be made available to everyone, eight months after their second dose, in response to waning antibody levels and a rise in breakthrough infections. People who took Pfizer, Moderna or J&J’s vaccines are still highly protected against hospitalization and death. This plan is not yet authorized. The agencies are also waiting for data to provide guidelines specific to J&J vaccine recipients in the coming weeks. Around a million people have gotten third shots so far in the US and abroad. The FDA hasn’t reviewed all of the data yet, but no new safety concerns have emerged thus far. See answers to frequently asked questions regarding the booster shots here.

August 22: Researchers published two case studies of patients experiencing neurological effects such as losing balance and non-epileptic convulsions after the Pfizer and AstraZeneca vaccines. They emphasize that functional neurological disorders are treatable.

September 2: Researchers in Israel reviewed medical records of patients who had experienced Guillan-Barre Syndrome (GBS) prior to receiving Pfizer’s COVID-19 shot. Of the 579 patients, five were transferred to the hospital for neurological symptoms such as tremors or prickling sensations. Only one patient required medical care for relapse of GBS.

September 28: V-Safe data from 306 people who received their third shots showed that nearly identical numbers of patients reported side effects to the second and third shots. 79.4% and 74.1% reported local or systemic reactions, respectively, after the third dose compared to 77.6% and 76.5% who reported local or systemic reactions after the second dose, respectively.


CanSinBio (China) 

China granted the CanSinBio vaccine emergency approval prior to beginning a Phase III trial in August. In the Phase II trial, nearly three-quarters of patients reported at least one common mild adverse events including injection site pain, rash, headaches, muscle soreness, and fevers. Five people also reported vomiting.


Gamaleya Research Institute (Russia)

Gamaleya Research Institute launched Phase III trials in August. But before they got started, President Putin announced that the vaccine was approved early, however, the Phase III trials are expected to continue. In the earlier trials, almost all of the patients experienced low-grade fevers. A small number of patients reported heart palpitations. Otherwise, reported side effects were similar to other vaccines and included injection site pain, rash, headaches, and muscle soreness.

Feb 2: The group reported efficacy data along with some data on side effects in The Lancet. The most common adverse events were flu-like illness (15.2% of those vaccinated) and local reactions (5.4% of those vaccinated).

The report also states that there were six grade 3 adverse events which were not associated with the vaccination: acute sinusitis, an exacerbation of urolithiasis along with renal colic and deep vein thrombosis (both associated with pre-existing comorbidities) and extremity abscess (due to physical injury and subsequent infection of the wound surface of the soft tissues of the finger).


Johnson & Johnson

Johnson & Johnson started a Phase III trial for its vaccine candidate in September 2020, but paused it on October 12 due to an unexplained illness and remains on hold. The company announced it would restart the trial on October 26. Pauses are common during clinical trials to evaluate specific adverse events, but the company has not shared details about the illness experienced by one of the trial volunteers. In earlier trials, about 70% of patients experienced at least one mild adverse effect similar to those seen with other vaccines, including injection site pain, rash, headaches, muscle soreness, and fevers.

On Feb 24, Johnson & Johnson shared data from its Phase III trials. The data suggested that while the vaccine is slightly less protective overall (but more protective against the 501Y.V2 variant that emerged from South Africa,) than the Moderna and Pfizer vaccines, it produced fewer side effects.

The report says the most common reactions were injection site reactions (50.2%), fatigue (38.2%), headache (38.9%), muscle pain (33.2%), nausea (14.2%) and fever (9.0%).  Reactions were more common in patients under 60 than over 60.

Injection site pain lasted a median of 2 days, but up to 7 days in 2.3% of patients.

April 8: A vaccination site in Colorado paused operations after 11 patients became nauseous and dizzy minutes after receiving the Johnson & Johnson vaccine. Two patients were transmitted to the hospital, but the rest were deemed healthy enough to return home. Officials said that those vaccinated at the same site should not be concerned.


April 13: The U.S. is calling for a pause on distributing the Johnson & Johnson vaccine while the FDA and CDC investigate blood clots that occurred in six patients (out of 7 million who received the vaccine so far.) One patient died and another was hospitalized. All the clots occurred in women under 50 within two weeks of receiving the vaccine. The issue is similar to the one seen with the AstraZeneca vaccine in Europe.

April 20: Researchers have received over 25,000 responses to an online survey regarding menstrual changes after receiving any COVID-19 vaccine. The survey is ongoing as researchers hope to gain a better understanding of future directions of research.

April 23: The U.S. is resuming use of the vaccine after finding only 15 total cases of blood clots out of the 7 million vaccinated. Patients will be warned about the risk at vaccination sites. Symptoms including headache, leg pain and abdominal pain occur 6-14 days after vaccination. If you have these symptoms you should seek emergency medical treatment. It is treatable with certain blood thinners.

April 26: MedShadow asked doctors about some of the unusual symptoms we’re hearing about in the comments: heart palpitations and visual disturbances. They hadn’t had patients who reported long-term symptoms, but said that if the symptoms occurred very quickly after vaccination, they could be related to allergic reactions or presyncope.

April 27: Doctors suggested that patients with a history of immune-mediated thrombocytopenia, such as heparin-induced thrombocytopenia, should not get the Johnson and Johnson vaccine (mRNA vaccines like Pfizer and Moderna are ok). If you’re at an increased risk for other types of blood clots, (because you have obesity or you smoke, for example) you do not have an elevated risk of blood clots with the J&J vaccine.

April 30: Researchers published detailed data about 12 patients who experienced blood clots in JAMA.

May 13: The CDC has identified more cases of the rare clotting disorder associated with the J&J vaccine. The total is 28 cases. Three patients have died and four are still hospitalized. It’s more common in women than in men, and the benefits still outweigh the risks of vaccination, officials say. Nine million doses of the vaccine have been delivered in the U.S.

May 26: A 37-year old woman in Belgium died from a blood clot thought to be related to the Johnson and Johnson vaccine she received. The country has stopped using the vaccine in patients under the age of 41.

July 12: The FDA is attaching a warning to the Johnson & Johnson vaccine about a slightly elevated risk of developing Guillain-Barre syndrome, which can cause paralysis, within three weeks of receiving the vaccine.  About 100 cases have been identified. Most patients recovered. One 57-year-old man died. The benefits still out weight the risks of vaccination, it says.

August 22: The FDA and CDC authorized third shots for patients with specific conditions that compromise their immune systems. The Biden administration has also pushed for booster shots to be made available to everyone, eight months after their second dose, in response to waning antibody levels and a rise in breakthrough infections. People who took Pfizer, Moderna or J&J’s vaccines are still highly protected against hospitalization and death. This plan is not yet authorized. The agencies are also waiting for data to provide guidelines specific to J&J vaccine recipients in the coming weeks. Around a million people have gotten third shots so far in the US and abroad. The FDA hasn’t reviewed all of the data yet, but no new safety concerns have emerged thus far. See answers to frequently asked questions regarding the booster shots here.


Astrazeneca

On September 6, the company paused the trial to investigate a patient who developed transverse myelitis – dangerous inflammation of the spinal cord. Researchers determined that the incident was unrelated to the vaccine and quickly restarted the trial in most countries, however it remained paused in the US until October 26. On October 21, scientists reported a patient in the trial had died, however, according to a local newspaper, the patient was in the control arm of the trial, meaning they’d received a placebo instead of the vaccine, so the trial is ongoing.

In earlier trials, many patients reported mild adverse effects similar to those associated with the other vaccines including injection site pain, rash, headaches, muscle soreness, and fevers. The team gave some of these patients preventative acetaminophen to reduce pain and fever. Nearly half of patients also experienced temporary neutropenia – a reduction in white blood cells that can make a person more susceptible to infections.

The vaccine has been approved for use in the U.K., Argentina, India, E.U. and Mexico.

March 11: Denmark has paused the use of the AstraZeneca vaccine while it investigates whether it is responsible for blood clots — one fatal — in some patients.

“It is important for us that the citizens are confident in the offer we give them and trust that we can vouch for the quality of the vaccines we have in our program. Therefore, we react promptly until we have investigated whether there is a connection between the vaccine and the possible side effects ,” officials wrote in a press release.

March 15: Several other countries (Iceland, Norway, Denmark, Ireland, the Netherlands, Italy, France and Germany) have also paused use of the vaccine while unusual clotting events are investigated. Meanwhile, Thailand, which paused its use on Friday, March 12 restarted it on Sunday, March 14. On Sunday, AstraZeneca released a statement that its own review revealed “no increased risk” of clotting issues with the vaccine and that “So far across the  EU and UK, there have been 15 events of DVT [deep vein thrombosis] and 22 events of pulmonary embolism reported among those given the vaccine, based on the number of cases the Company has received as of 8 March. This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed COVID-19 vaccines.”

March 18: The European Medicines Agency (EMA) issued a statement that the benefits of the AstraZeneca vaccine outweigh the risks. The vaccine is not associated with an overall risk of blood clots, though there may be a very small increased risk of certain types of clots. The statement reads, “These are rare cases – around 20 million people in the UK and EEA had received the vaccine as of March 16 and EMA had reviewed only 7 cases of blood clots in multiple blood vessels (disseminated intravascular coagulation, DIC) and 18 cases of CVST [clots in the vessels that drain blood from the brain.] A causal link with the vaccine is not proven, but is possible and deserves further analysis.” These cases were more common in women under the age of 55. Germany, France, Italy, Latvia, Bulgaria and Slovenia have all stated that they’d restart or continue to offer the AstraZeneca vaccine in light of the news.

April 7: The EMA still says the benefits of the vaccines outweigh the risks. However, the group has suggested that blood clots be listed as a possible, albeit rare, side effect of the injection and that both patients and doctors be aware of the signs which include: shortness of breath, chest pain, leg swelling, persistent abdominal pain, neurological symptoms like blurry vision and blood spots under the skin beyond the site of injection. If you have these symptoms, seek medical assistance.


April 9: Out of 34 million recipients of the vaccine, 222 have reported blood clots. They appear to be more likely in younger patients, but it’s otherwise impossible to predict who will experience them. Some experts say they can be treated with intravenous immune globulin, which is currently used to treat immune disorders along with some types of blood thinners.

June 9: A study in Nature Medicine suggests that there may be a very slightly elevated risk of blood disorders after receipt of the AstraZeneca vaccine, but not Pfizer’s. The study was based on an analysis of medical records in Scotland. Researchers say the vaccine’s benefits still outweigh the risks and that their results should not alter policy. The rates are similar to those seen with other common vaccines.

August 22: Researchers published two case studies of patients experiencing neurological effects such as losing balance and non-epileptic convulsions after the Pfizer and AstraZeneca vaccines. They emphasize that functional neurological disorders are treatable.


Novavax (United Kingdom)

Novavax began Phase III clinical trials with its vaccine candidate in the United Kingdom in September and is had planned to start a trial in the United States in October. The trial was delayed due to manufacturing problems. The U.S. trial started on December 28. During Phase I/II trials, patients reported adverse events similar to those of other vaccine candidates, including injection site pain, rash, headaches, muscle pain, fever, nausea and vomiting. 

June 14: Novavax announced promising efficacy data in a press release. The release suggested that the vaccine has similar side effects to others already approved, but that they may be slightly milder. Complete data is not yet available.


 Sinopharm (China) 

In July, Sinopharm launched Phase III trials of its two vaccine candidates in the United Arab Emirates, Peru, Morocco, and Argentina, which are now approved for limited use in healthcare workers in China and the UAE. In earlier trials of one of the vaccines, made in collaboration with Wuhan Institute of Biological Products, about 15% of the patients reported adverse events similar to those of other vaccine candidates, including injection site pain, rash, headaches, muscle pain, fever, nausea and vomiting. There is little data available about the second vaccine, made in collaboration with the Beijing Institute of Biological Products.


Sinovac (China)

Sinovac opened Phase III trials of its vaccine candidate, CoronaVac, in July. It is already being used with emergency approval for high risk individuals in China. The earlier trials showed that about a third of patients experienced adverse effects similar to those in other vaccine candidates like injection site pain, fever, and fatigue, but the study included few details about more specific symptoms like nausea, headaches, and vomiting. On November 10, the trial was halted in Brazil due to a participant’s death. However, researchers say the death was not vaccine-related and the trial should continue. It has not been halted in other countries.


Murdoch Children’s Research Institute (England)

The Murdoch Children’s Research Institute is running a Phase III trial repurposing Bacillus Calmette-Guerin — a vaccine developed nearly a century ago to prevent tuberculosis infections — to prevent Covid-19. Since the vaccine has been around such a long time, there are many reports on its potential adverse effects and the vaccine itself has been altered to minimize many of them. Injection site reactions are common, and lymphadenitis, swelling of the lymph nodes, is common.  

Bharat Biotech

Bharat Biotech announced it would begin Phase III trials in India on October 23. In early trials demonstrated side effect profiles similar to those of the other vaccines, including pain at the injection site, fatigue, headache, and fever. The country announced emergency approval, though no Phase III data was included in the announcement.

 


Did you find this article helpful?


Subscribe
Notify of
guest
1.4K Comments
Inline Feedbacks
View all comments
Dave
Dave
1 day ago

https://www.medrxiv.org/content/10.1101/2021.10.14.21265010v1

Out of almost 7000 who got the vaccines (any of the 3 – Pfizer, Moderna, J&J).

Hospitalization 0.3% and severe allergic reactions 0.6%. (Very roughly 1 in 1000 and 1 in 2000, with 1000-2000 people the population of some high schools.)

Those with autoimmune disease or lung disease were approximately twice as likely to seek medical care.

Tatiana
Tatiana
12 days ago

Please watch this press conference. Ex famous football player and his wife are helping those who need a voice in this. I will list the link here of the televised press conference with Senator Johnson and also the organization you can contact privately to voice your concerns:
https://youtu.be/6mxqC9SiRh8
https://www.c19vaxreactions.com
I hope this information is useful in gaining understanding and helping us all along with this extremely complex situation.

Saba
Saba
17 days ago

I wanted to come back here and post a positive story about insomnia issues after the vax. You can see my previous posts of desperation from back in March. 42 y/o male, with no health issues prior to vax. Rather I was very athletic and best shape ever. First and only Moderna on 03/19/21. Did not take the 2nd shot due to the side effects. I had severe insomnia starting the next night. It is hard to describe the hell I went through because of insomnia for almost over 5 months. Nothing, even rx meds didn’t work, especially the first… Read more »

Jack
Jack
19 days ago

4 months in from first jab of Moderna and struggling with my chest and unable to sleep at night. Any kind of physical activity triggers a chest pain as if I had fragments of glass inside. At night, anxiety hits me and unable to get any sleep and if I do I worry that I’ll even wake up the next day.

Dave
Dave
20 days ago

https://www.news-medical.net/news/20210930/Comparison-of-Pfizer-Moderna-JJ-AZ-vaccines-for-neutralization-titer-against-Delta-and-other-variants.aspx

“A one-dose Moderna vaccine had the highest antibody titers compared to all three vaccines.”

This reflects the fact that Moderna has been reported to contain a “higher amount of active ingredient in the Moderna vaccine — 100 micrograms, versus 30 micrograms in Pfizer”.

https://www.bloomberg.com/news/articles/2021-08-31/moderna-jab-spurs-double-pfizer-covid-antibody-levels-in-study

SO, if one must get the vaccine, Moderna would provide the best protection regardless of what side effects vaccines create.

Dave
Dave
22 days ago

We found that 1095 patients (45.0%) reported at least 1 symptom, and the most common symptoms were fatigue, sweating, chest tightness, anxiety, and myalgia. Older age, female gender, and severe disease were associated with higher risks of fatigue or more symptoms. In total, 161 patients (6.6%) had CAT total scores of at least 10, for which the risk factors included severe disease during hospital stay or coexisting cerebrovascular diseases.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784558

Would be interesting to see what percentage of the vaccinated but never infected get long term side effects.

Dave
Dave
22 days ago

JAMA Network Open full text iconFULL TEXTcontents iconCONTENTSfigure iconFIGURES / TABLESattach iconSUPPLEMENTAL CONTENTreferences iconREFERENCESrelated iconRELATEDcomments iconCOMMENTS Download PDF Comment Top of Article Key Points Abstract Introduction Methods Results Discussion Conclusions Article Information References Figure 1. Study Flowchart Study Flowchart Figure 2. Total and Item CAT Scores in Patients at 1-Year Follow-up Total and Item CAT Scores in Patients at 1-Year Follow-up ADL indicates activities of daily living; CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease. Table 1. Characteristics of Enrolled Patients Characteristics of Enrolled Patients Table 2. Symptoms at 1-Year Follow-up According to Disease Severity Symptoms at 1-Year Follow-up… Read more »

ConcernedVaxxer
ConcernedVaxxer
1 month ago

5 days after getting the 1st dose of the Pfizer vaccine I developed swelling, bruising, pain and redness in my breast. There is a large area of very dark bruising, swollen lymph nodes that are raised and visible through the skin and tenderness to the touch. The symptoms are only in my left breast which is the same side I had the vaccine injection (left arm). It’s been almost two months and I still have daily breast pain, bruising and minor swelling in the left breast. My doctor gave me Prednisone and the symptoms went away while I was taking… Read more »

David
David
1 month ago

Report your adverse reaction to the vaccine at the VAERS website: https://vaers.hhs.gov/reportevent.html
I myself took the second dose of Moderna back on April 30. Four days later I began to experience heart palpitations / skipped heart beats that lasted for months. My primary care physician and a different cardiologist told me they didn’t think the vaccine was the direct cause (yeah, right). Anyway, I got myself on magnesium citrate and the palpitations have thankfully gone away.

Robert
Robert
1 month ago

I don’t claim any medical knowledge. I’ve not taken the vaccines and don’t intend to. But I have a question and hope it’s answerable. My wife’s 63 year old brother, in the Philippines, very healthy person, got his second dose of Pfizer two days ago. He collapsed there in the clinic and was rushed to the hospital. He has no history of any medical issues. Sadly, his kidneys had immediately started shutting down and he died less than two days later. I’m not looking for pro or anti vaxx arguments, I respect whatever you choose for yourself and feel that’s… Read more »

Dave
Dave
1 month ago

https://www.yahoo.com/news/pfiizer-picked-covid-19-vaccine-125332549.html

“Pfizer’s top scientist said it chose a relatively low COVID-19 vaccine dose to minimize side effects.

Pfizer’s vaccine has 30 micrograms of mRNA, the active ingredient. Moderna’s has 100 micrograms.”

Or…… Pfizer is giving us less than 1/3rd the ingredients needed for great protection, or Moderna is gonna cause us lots more side-effects….

Vaers does report More Moderna events than Pfizer events, supporting this (more Pfizer doses given).
https://wonder.cdc.gov/

https://www.seattletimes.com/nation-world/new-data-confirm-pfizer-and-moderna-vaccines-bring-a-small-risk-of-heart-problems/

That said, the latest data shows an increased risk of Heart Problems after Pfizer/Moderna vaccination, so those with current heart disease should weigh the pros and cons.

Dave
Dave
1 month ago

https://doi.org/10.1056/NEJMoa2110475 Data from 2.4 million vaccinated Israelis show that the “Pfizer” vaccine have these side-effects: “In short, the study has shown that vaccination was strongly associated with an increased risk of myocarditis (2.7 events per 100,000 persons), as well as lymphadenopathy (which occurred relatively frequent with 78.5 events per 100,000 persons), herpes zoster infection (which can translate to an increased risk of Bell’s palsy) and appendicitis. On the other hand, SARS-CoV-2 infection was linked to a substantially elevated risk of myocarditis (11 events per 100,000 persons), alongside the risk of pericarditis, arrhythmia, pulmonary embolism, deep-vein thrombosis, myocardial infarction, thrombocytopenia, and… Read more »

Sam
Sam
1 month ago

I had the Moderna shot just over two months ago and have suffered from burning tingling sensations all over my body, including some dizziness and light-headedness in the mornings off and on. Has anyone taken Gabapentin and if so, has it worked or have you needed to keep upping your dosage? What about natural treatments? Very frustrating and it’s waking me up all hours of the night,,,,, suggestions???

Dave
Dave
1 month ago

https://japantoday.com/category/national/moderna-says-tainted-covid-vaccines-sent-to-japan-contained-steel
Steel particles found in some batches of Moderna in Japan. Don’t be surprised if you got a jab with such batches and have side effects!

You can always ask the caregiver to visual check the vial for foreign particles prior to giving you a dose.

Jay
Jay
1 month ago

I will be waiting for Novavax approval here in Canada. The phase trials looked very good, and the amount of research and data available regarding protein sub unit vaccines is comforting. Also, I love how they are using an adjuvant sourced from a tree unlike from aluminum like post protein sub units have.

Jess
Jess
1 month ago

Hello!! I just wanted to get an update on how you guys are feeling. I’m in the Oz and as with most ppl, we are being forced to take the vaccine. My dr has advised me to take the Pfizer butbive had severe anxiety for the past few weeks thinking about the thought of taking it. I’ve had severe anxiety and panic attacks on the past to a point that I was admitted to hospital. I’m so so terrified that this vaccine may trigger these or if I can handle getting these again. My partner is booked to have his… Read more »

Dave
Dave
1 month ago

https://japantoday.com/category/national/Japan-halts-use-of-1.63-mil-Moderna-vaccine-doses-over-contamination

https://time.com/5955247/inside-biontech-vaccine-facility/

Don’t be too surprised if some of the side effects are due to manufacturing defects of the vaccines.

After all, any 50,000 step process created literally on-the-fly in 2020 and rushed out the door is bound to have a few things wrong.

The companies are improving the process over time, but any single error in a 50,000 step process can make a bad batch.

Jody
Jody
2 months ago

I have not been on here in a few months. I took Pfizer–second vaccine 3/15. I was diagnosed with costochondritis prior to vaccine but it came and went. Over 5 months later, I have been diagnosed with thoracic radiculopathy-very rare and intercostal neuralgia. My PCP in the beginning brought up vaccine side effects and I agreed. I am bedridden and in chronic pain every day. My pain is a 10 plus, I have disc bulge at T6T7–thoracic MRI. I had thoracic ESI and trigger points. Spinal surgeon wants to do one more ESI to rule out spine causing the problem.… Read more »

Dave
Dave
2 months ago

https://twitter.com/washingtonpost/status/1425509755481563139?s=19

Survivor Corps founder Diana Berrent joins The Post to discuss the growing number of people with long-haul COVID, the mounting medical challenges they face and her own experience with lingering symptoms.

Reasons for vaccination…

Dave
Dave
2 months ago

https://www.heraldscotland.com/news/19442038.coronavirus-scotland-41-covid-deaths-date-among-fully-vaccinated-scots/ What’s important is the graph breakdown of those infected – unvaccinated vs vaccinated. 65% of the infected were not vaccinated 35% of the infected were vaccinated That’s 7 out of every 20 infected people got vaccinated! This simply reflects the dropping efficacy of vaccines against new strains of covid. … And, notice the 10000s infected! Vs Wuhan China. They shut the city down, burned out the virus, and for about a year, no, that’s zero 0, infections until the delta recently arrived. Then they tested all 11 million, and found a few dozen in Wuhan (and a few hundred… Read more »

Dave
Dave
2 months ago

https://www.news-medical.net/news/20210806/Double-vaccinated-three-times-less-likely-to-test-positive-for-COVID-19-than-unvaccinated-says-study.aspx Vaccine effectiveness is dropping fast. In the latest round of people studied in the UK, “in round 13 (June 24 and July 12, 202 1), 44 percent of infections happened in fully vaccinated people…” From the latest August data from LA County health, 0.31% of the vaccinated tested positive (infected). That’s 1 person out of 322 vaccinated STILL getting infected. Out of these 15,628 vaccinated and infected, 446 died. Or 1 out of 33 infected AND vaccinated DIE. N95 or N100 mask use, distancing, isolating, and simply not seeing anyone in person recommended for the highest risk age groups,… Read more »

Dave
Dave
2 months ago

https://www.news-medical.net/news/20210806/Study-reports-on-COVID-19-vaccine-related-adverse-events-in-young-Japanese-population.aspx

In Japan, the latest data says:

“Vaccination at the workplace was administered to approximately 4,000 people. About 0.5% of vaccine recipients had adverse events..”

So that’s 1 in 200 people suffering effects such as anaphylaxis.

Dave
Dave
2 months ago

https://www.nature.com/articles/d41586-021-02039-y Extremely detailed overview of the way Covid virus attacks human cells, invades them, and the important effects. One of the key differences between vaccination and infection in creating immunity is syncytia covid infections. Syncytia occurs when several cells fuse or bind together to create a “lump” of cells. This occurs in the lungs in covid infections, but not from vaccinations. Widespread syncytia leads to the extensive lung damage and inability to breathe well often seen in covid patients (and this is aside from the damage caused when the patients often catch pneumonia as a result of covid infection). Naturally,… Read more »

Dave
Dave
2 months ago

https://www.news-medical.net/news/20210731/FDAs-accelerated-drug-approval-process-plagued-by-missing-efficacy-data-and-questionable-evidence.aspx “Since the US Food and Drug Administration (FDA) established its accelerated approval pathway for drugs in 1992, nearly half (112) of the 253 drugs authorized have not been confirmed as clinically effective, an investigation by The BMJ has found.” While we know the vaccine works to a degree (the recent superspreading infections among the vaccinated reveal poor protection against infection, but decent protection against death after infection among the vaccinated – 1 in 100 among the infected vaccinated based on LA county data), we still don’t know the extent of the short and long term side effects. … That… Read more »

Dave
Dave
2 months ago

“Decreased appetite, lethargy, asthenia, malaise, night sweats, and hyperhidrosis were new adverse events attributable to BNT162b2 (Pfizers mRNA covid vaccine).”

“More BNT162b2 than placebo recipients reported local reactions, most commonly mild-tomoderate injection site pain.”

“More BNT162b2 than placebo recipients reported systemic events, most commonly fatigue. Systemic events were mostly mild-to-moderate, but occasionally severe.”

Efficacy dropped to 83.7% (74.7 to 89.9% range) after 4 months post-vaccination.

Importantly!
Right after the 2nd dose, the efficacy in some groups was poor.
Eg. Asians 87.6% (range as low as 58.9 to 96.6%).

https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf

Latest News

Covid-19: Side Effects of Trump’s Treatments

Covid-19: Side Effects of Trump’s Treatments

President Donald Trump announced (via Twitter, of course) what some considered unthinkable, and others considered inevitable — that he had tested positive for Covid-19. Over the weekend, he received various treatments  — supplements like vitamin D, zinc and melatonin, an experimental antibody combination, an antiviral drug and a powerful anti-inflammatory…

Un-Sheltering Tips for Your Health and Immune System

Un-Sheltering Tips for Your Health and Immune System

As we all emerge from our bubbles of limited contact with others, we are walking straight into the double whammy of flu season and COVID-19 germs. Can your body fight off exposure to the flu and COVID? Your immune system feeds off the basics of life — sleep, movement, food…